GA
ARQT icon

Greenspring Associates’s Arcutis Biotherapeutics ARQT Stock Holding History

Greenspring Associates’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-35,210
Closed -$961K – 1
2021
Q2 		$961K Buy
+35,210
New +$992K 0.07% 9

Other funds holding ARQT

FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Greenspring Associates's ARQT Position: Q3 2021 in Review

Greenspring Associates sold out of Arcutis Biotherapeutics (ARQT) in Q3 2021, closing a stake of 35,210 shares — an estimated $961K sold.

Greenspring Associates first reported a position in ARQT in Q2 2021 and held it in 1 quarter. The position peaked at $961K in Q2 2021. 103 funds tracked by Wall St. Rank hold ARQT as of Q3 2021.

  • Greenspring Associates reported no remaining Arcutis Biotherapeutics position as of Q3 2021 after selling out during the quarter.
  • Greenspring Associates sold 35,210 Arcutis Biotherapeutics shares in Q3 2021, an estimated $961K.
  • Greenspring Associates first reported a position in Arcutis Biotherapeutics in Q2 2021 and held it in 1 quarter.
  • Greenspring Associates's Arcutis Biotherapeutics position peaked at $961K in Q2 2021.
  • 103 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q3 2021.

Based on Greenspring Associates's 13F filing for Q3 2021.